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ABSTRACT 
 
G protein-coupled receptor kinase 2 (GRK2) emerges as a key modulator of G 
protein-coupled receptors and other plasma membrane receptors triggered by chemotactic 
messengers. In addition, GRK2 has been reported to interact with a variety of signal 
transduction proteins related to cell migration. Interestingly, the levels of expression and 
activity of this kinase are altered in several inflammatory disorders, thus suggesting that it 
may play an important role in the onset or progression of these pathologies. This review 
summarizes the mechanisms involved in the control of GRK2 expression and function and 
highlights novel functional interactions of this protein that might help to explain how 
altered GRK2 levels affects cell migration in different cell types and pathological settings. 
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RESUMEN 
 
Papel de GRK2 (G protein-coupled receptor kinase 2) en migración e inflamación 
 
La quinasa GRK2 (G protein-coupled receptor kinase 2) se perfila como un 
modulador clave de receptores acoplados a proteínas G y de otros receptores de 
membrana plasmática que responden a estímulos migratorios. Además, GRK2 es capaz de 
interaccionar con diferentes proteínas señalizadoras relacionadas con la migración celular. 
Por otra parte, puesto que los niveles de expresión y actividad de esta quinasa se 
encuentran alterados en distintas en enfermedades inflamatorias, se sugiere que GRK2 
puede desempeñar un papel importante en el desencadenamiento o la progresión de estos 
procesos. Esta revisión resume los mecanismos implicados en el control de la expresión y 
función de GRK2 y resalta nuevas interacciones funcionales de esta proteína que pueden 
contribuir a explicar cómo las alteraciones en los niveles de GRK2 afectan a la migración 
de distintos tipos celulares y a diversas situaciones patológicas. 
 
Palabras clave: GPCR.- Arrestinas.- GIT.- p38MAPK.- MEK. 
 
 
 
INTRODUCTION 
 
Signal-directed migration requires a spatio-temporal integration of 
information arising from mechanical cues and from diffusible molecules 
such as chemokines, bioactive lipids and growth factors. Failures in this 
process might result in aberrant migration leading to chronic inflammatory 
disorders, tumor metastasis, impaired wound healing or other diseases (1). 
Key messengers involved in cell migration (such as chemokines or 
sphingosine-1-phosphate, S1P) emit signals to the actin cytoskeleton and to 
adhesion structures by binding to plasma-membrane receptors of the 
GPCR family (2, 3). 
GRK2 is a ubiquitous member of the G protein-coupled receptor 
kinase family, a group of seven serine/threonine protein kinases that 
specifically recognize and phosphorylate agonist-activated G protein-
coupled receptors (GPCRs). GRK2-mediated receptor phosphorylation 
triggers the binding of cytosolic proteins termed arrestins, which block the 
ability of GPCR to interact with G proteins, leading to rapid 
desensitization. As a result of β-arrestin binding, phosphorylated receptors 
are also targeted for clathrin-mediated endocytosis, a process that 
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classically serves to re-sensitize and recycle receptors back to the plasma 
membrane, but may also help to promote the activation of additional 
signalling pathways by way of arrestins and/or GRKs acting as agonist-
regulated adaptor scaffolds (4, 5). Interestingly, GRK2 expression and 
function has been shown to be altered in several inflammatory conditions 
(see below), thus suggesting that it may play an important role in the onset 
or progression of the inflammatory disease. Therefore, the understanding 
of the molecular mechanisms leading to altered GRK2 levels and 
functionality, as well as of the consequences of such changes on key 
cellular processes is a very active field of research. 
Consistent with its role in GPCR desensitization, GRK2 has been 
shown to attenuate chemokine-induced migration in T cells and monocytes 
(revised in (6)), thus emerging as a relevant modulator of inflammatory 
responses. However, pro-migratory effects for β-arrestins and for a 
member of a distinct GRK subfamily, GRK6, have also been reported in 
response to different GPCR in several cell types (2, 6), thereby suggesting 
other unknown functional roles different to those related to GPCR 
desensitization. 
Interestingly, in addition to phosphorylate a variety of GPCR, 
recent data indicate that GRK2 is also able to phosphorylate other types of 
membrane receptors, such as the PDGF-receptor, and non-receptor 
substrates as tubulin, the ERM family protein ezrin, or the p38 MAPK (see 
(4, 5, 7) and references therein). Thus, GRK2 may participate in the 
regulation of diverse cellular phenomena through the phosphorylation of 
substrates that are very varied functionally. Moreover, GRK2 has been 
shown to interact with a variety of proteins involved in migration (MEK, 
Akt, PI3Kγ or GIT (reviewed in (5)). In this review we will briefly 
summarize the main mechanisms involved in the control of GRK2 
expression and function, its reported alterations in inflammatory disorders 
and the emerging functional interactions of GRK2 with diverse molecules 
related to cell migration and inflammation (see Figure 1) that may shed 
new light on how GRK2 influences motility in different cellular types and 
on the physiological consequences of altering the cellular complement of 
this kinase. 
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FIGURE 1.- GRK2 functionally interacts with multiple signalling proteins involved in cell 
migration. See text for details. 
 
 
GRK2 STRUCTURE AND MODULATION 
 
GRK family members can be subdivided into three main groups 
based on sequence homology: rhodopsin kinase or visual GRK subfamily 
(GRK1 and GRK7), the β-adrenergic receptor kinase subfamily 
(GRK2/GRK3) and the GRK4 subfamily (GRK4, GRK5 and GRK6). 
GRK2, 3, 5 and 6 are ubiquitously expressed in mammalian tissues. 
GRKs share a common structural architecture with a well-
conserved, central catalytic domain (~270 aa), similar to that of other 
serine-threonine kinases, flanked by an N-terminal domain (~185 aa) and a 
variable-length carboxyl-terminal domain (~105-230 aa). The N-terminal 
domain has been proposed to be important for receptor recognition, for 
intracellular membrane anchoring and also contains an RH domain 
(regulator of G protein signalling homology domain) of ~120 aa. In the 
case of GRK2 and GRK3, the RH domain has been shown to specifically 
interact with Gαq family members, thus blocking its interaction with their 
effector phospholipase C beta. The C-terminal region of GRK2 contains a 
pleckstrin homology domain (PH) with binding sites for the membrane 
phospholipid PIP2 and free Gβγ subunits and therefore is involved in its 
agonist-dependent translocation to the plasma membrane (4, 5). 
In addition to this general domain architecture, ongoing research is 
unveiling the existence of regions involved in interaction with different 
cellular proteins and of regulatory phosphorylation sites in the GRK2 
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structure. Association with actinin, actin, calmodulin, caveolin, the Raf 
kinase inhibitor protein (RKIP) or with an undetermined microsomal 
component negatively modulates GRK kinase-dependent functions. In 
addition, phosphorylation of GRKs at different sites and by a variety of 
protein kinases has emerged as an important mechanism for regulation of 
their activity, the interaction with other proteins and even protein stability 
(4, 5). 
 
 
REGULATION OF GRK2 BY PHOSPHORYLATION 
 
Phosphorylation by second-messenger-modulated protein kinases (PKC 
and PKA). 
PKC and PKA have been shown to modulate GRK activity and 
membrane targeting. “In vitro”, PKC-mediated phosphorylation of GRK2 
led to an enhanced phosphorylation of receptor but not soluble peptides, 
suggesting that PKC phosphorylation stimulated GRK2 translocation from 
the cytosol to the plasma membrane without affecting catalytic activity. It 
has been recently reported that phosphorylation of GRK2 by PKC takes 
place at serine 29 (8) within the calmodulin-binding region of GRK2. It 
has been suggested that in intact cells a pool of GRK2 may be tonically 
inhibited by forming a complex with calmodulin, and that PKC 
phosphorylation would release such inhibitory interaction and allow for 
GRK2 binding to the receptor substrate (8). 
On the other hand, PKA activated by Gs-coupled receptors can 
directly phosphorylate GRK2, leading to an enhanced GRK2 activity 
toward β2-adrenergic receptors (9). The site of PKA phosphorylation on 
GRK2 was mapped at Serine 685, which is in close proximity to the Gβγ 
binding domain of GRK2. In fact, PKA phosphorylation does not affect the 
kinase activity, but rather enhances binding of GRK2 to Gβγ subunits, 
thereby facilitating membrane targeting of GRK2 and interaction with 
activated receptors. 
 
Phosphorylation by c-Src and MAPK. 
c-Src can directly phosphorylate GRK2 “in vitro” with high affinity 
and also promotes tyrosine phosphorylation of GRK2 upon agonist 
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stimulation of β2-adrenergic receptors (10). This process is dependent on 
the ability of β-arrestins to recruit c-Src (11). The activity of tyrosine-
phosphorylated GRK2 is increased toward both soluble and membrane-
bound substrates, suggesting a direct effect on its catalytic activity. 
Mutagenesis experiments have identified tyrosine residues within the RH 
region of GRK2 (amino acids 13, 86 and 92) that are critical for c-Src-
mediated phosphorylation. Tyrosine phosphorylation also appears to 
enhance the interaction of GRK2 with Gαq (12) and to promote its 
degradation by the proteasome pathway (see below). 
GRK2 activity is also regulated by p42/p44 MAPK. “In vitro” and 
“in situ” experiments revealed that ERK1 is able to phosphorylate 
recombinant GRK2 on serine 670 (13, 14), and both kinases are 
specifically co-immunoprecipitated in an agonist-dependent manner (13). 
Interestingly, Serine 670 lies within the Gβγ binding domain of GRK2, and 
MAPK phosphorylation of this site strongly impairs the GRK2/Gβγ 
interaction, thereby inhibiting kinase translocation and catalytic activity 
toward receptor membrane substrates. 
 
 
REGULATION OF GRK2 EXPRESSION LEVELS 
 
Little has been reported about the mechanisms governing GRK 
transcription. In aortic smooth muscle cells, agents that induce 
physiological vasoconstriction and hypertrophy markedly enhance GRK2 
promoter activity, whereas pro-inflammatory cytokines promote the 
opposite effect, suggesting that the expression of GRK2 is strongly 
controlled at the transcriptional level by the interplay between various 
signal transduction pathways (15). However, whether these mechanisms 
apply to other cell types awaits further investigation. 
On the other hand, regulation of GRK2 stability may provide an 
important mechanism for modulating its expression levels (Figure 2). 
GRK2 is rapidly degraded by the proteasome pathway, and β2AR 
activation enhances GRK2 ubiquitination and turnover (16). Our 
laboratory has also shown that agonist-dependent binding of β-arrestin to 
GPCR supports GRK2 degradation by allowing the recruitment of c-Src 
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and the phosphorylation of GRK2 on critical tyrosine residues (11). 
MAPK-mediated GRK2 phosphorylation also triggers GRK2 degradation 
in a process which is again dependent on β-arrestin function (17). More 
recently, we have shown that Mdm2, an E3-ubiquitin ligase involved in the 
control of cell growth and apoptosis, plays a key role in GRK2 degradation 
(18). Mdm2 and GRK2 association and subsequent proteolysis is enhanced 
by β2-adrenergic receptor stimulation and β-arrestin. On the contrary, 
activation of the PI3K/Akt pathway by agonists such as IGF-1 alters 
Mdm2-mediated GRK2 degradation, leading to enhanced GRK2 stability 
and increased kinase levels, what might be relevant in several 
pathophysiological contexts. 
 
 
 
FIGURE 2.- Mechanisms involved in the regulation of GRK2 stability. See text for details. 
 
 
GRK2 levels might also be downregulated by additional proteolytic 
pathways. Rheumatoid arthritis (RA) patients display significantly reduced 
GRK2 levels in peripheral blood mononuclear cells (PBMC) without 
significant changes in GRK mRNA levels. The same is observed in rats in 
an animal model of adjuvant arthritis (6). Proinflammatory cytokines as 
IL-6 and INFγ are elevated in patients with RA, and treatment of PBMC 
with these compounds strongly promotes GRK2 down-regulation. 
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Production of reactive oxygen species (ROS) has been detected in different 
cells treated with these cytokines, suggesting that ROS could mediate the 
decrease in GRK2 levels observed in these experimental models of 
inflammation. In fact, it has been recently described that exposure of 
lymphocytes to oxidative stress results in decreased GRK2 levels in T 
lymphocytes (19). Interestingly, the H2O2-induced decreases in GRK2 
protein were prevented by inhibiting calpain activity, but not proteasome 
function. “In vitro” proteolysis experiments show that purified m-calpain 
promotes partial degradation of GRK2 in a calcium-dependent way (19). It 
is tempting to suggest that calpain-mediated degradation of GRK2 could 
also play a role in other situations characterized by altered calpain activity 
and GRK levels, such as hypertension. Overall, these results indicate the 
occurrence of different proteolytic pathways for GRK2 down-regulation 
(proteasome- and calpain dependent). How these mechanisms are activated 
and contribute to the control of GRK2 stability in a given cell type and 
physiological condition is an interesting area of future research. 
 
 
GRK2 AND INFLAMMATORY DISORDERS 
 
GRK2, which is highly expressed in different cellular types of the 
immune system, emerges as an important regulator of the immune cell 
responses during inflammation. GRK2 phosphorylates manifold 
chemokine receptors such as CCR5, CCR2b, CXCR4, CXCR2 and 
chemotactic receptors for substance P, S1P or formyl-peptide, responsible 
of leukocyte trafficking to the inflammatory foci, T cell egression from 
lymphoid organs, leukocyte activation or proliferation (6). Interestingly, a 
decrease of GRK2 protein expression (~55%) and kinase activity was 
found in peripheral blood mononuclear cells of patients with rheumatoid 
arthritis (RA), as compared with kinase levels in healthy subjects (20). The 
decline of GRK2 is a direct consequence of the pathology as demonstrated 
in animal models of experimental arthritis (21), which specifically show a 
reduction in GRK2 levels in splenocytes and mesenteric lymph node cells. 
Down-regulation of GRKs in immune cells during inflammation may 
represent initially an adaptive mechanism to facilitate cell response, but 
chronic GRK2 down-regulation can lead to an aberrant inflammatory 
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response. Indeed, T cells from GRK2+/- mice, that display a 50% reduction 
in GRK2 levels, showed a significant increase in signalling and chemotaxis 
toward CCR1 and CCR5 receptor ligands compared to wild-type T cells 
(22). However, whether GRK2 expression levels are determinant for the 
progression of RA still requires further evidence. Interestingly, such notion 
was indeed demonstrated for another inflammatory disorder, i.e. multiple 
sclerosis (MS) (23). Expression of GRK2 in leukocytes from patients 
suffering from MS, but not from neurological disorders without an 
inflammatory component, was also decreased by circa 40% compared with 
kinase levels from healthy individuals. GRK2 levels have a direct impact 
in the clinical course of experimental MS. Thus, the onset of the relapsing-
remitting experimental autoimmune encephalomyelitis (EAE) in 
hemizygous GRK2+/- mice was significantly accelerated, what is paralleled 
by a higher initial infiltration of T cells into the brain. Curiously, these 
animals display lower inflammatory infiltrates in the long-term and do not 
develop relapses of the disease compared to wild-type animals. Reactive 
microglia and neuronal damage secondary to excessive glutamate 
signalling are important components of diverse neurological disorder that 
course with inflammation. Interestingly, GRK2 expression levels in brain 
also modulates the strength of microglia-mediated inflammation, what 
might determine the sensitivity to cerebral stroke by means of rate-limiting 
the extent of local release of inflammatory mediators that could attract T 
cells (24). Therefore, the effects of altered GRK2 expression are far to be 
clear-cut in terms of inflammation, since many different cell types, not 
only from the immune system but also from the inflamed tissue, are 
responsible for the course of the disease and can respond distinctly to 
GRK2 changes. 
Brain GRK2 also modulates the strength of microglia-mediated 
inflammation and its protein expression levels might determine the 
sensitivity to cerebral stroke (24). Reactive microglia and neuronal damage 
secondary to excessive glutamate signalling are important components of 
AD pathology. Recently, a study aimed to evaluate peripheral lymphocyte 
GRK2 expression in patients suffering from AD has shown a positive 
correlation between kinase protein levels and the severity of the disease 
(25). 
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NOVEL GRK2 FUNCTIONAL INTERACTIONS MIGHT BE 
RELATED TO THE ROLE OF THIS KINASE IN INFLAMMATION 
AND CELL MIGRATION 
 
GRK2 as a modulator of the MEK/ERK interface upon chemokine 
challenge 
We have recently reported, using GRK2-transfected cells or 
splenocytes from heterozygous GRK2 mice, that elevated levels of GRK2 
can inhibit chemokine-mediated induction of ERK activity and, on the 
contrary, that decreased levels of GRK2 promote a more robust ERK 
activation upon agonist treatment. Neither the kinase activity of GRK2 nor 
its interaction with G protein subunits is necessary for this inhibitory effect 
and no changes were observed in the extent of MEK activation in our 
experimental settings. Interestingly, we have found that GRK2 and MEK1 
are present in the same multimolecular complex and that this interaction 
correlates with an inhibition of ERK activation, that involves a direct or 
coordinate interaction with MEK (26). Thus, this association seems to be 
important in the control of chemokine induction of MAPK activation hence 
for the extent of chemotactic cell motility. By binding to MEK, GRK2 
could interfere (at the cellular level or at defined cellular locations) with 
MEK association to proteins important for its cellular compartimentation, 
internalization, or activity, such as MEK-ERK scaffolds. Therefore, 
changes in GRK2 expression in pathological conditions would alter 
chemokine receptor signaling at different levels. 
 
GRK2/p38 MAPK 
We have found that GRK2 directly phosphorylates p38α at the 
Thr123 residue located at the entrance of the p38 docking groove (7). 
Mimicking phosphorylation of this residue interferes with the binding and 
phosphorylation of well-established p38 substrates (ATF2, MEF2, MK2), 
and also with the ability of p38 to bind and become phosphorylated by 
MKK6 in vitro and in cells. This phosphorylation has an impact on p38-
dependent cellular functions, since changing GRK2 levels alters the 
secretion of TNFα upon LPS stimulation, this process being increased in 
GRK2+/- murine macrophages. 
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Kinases upstream p38 have been classically involved in its 
activation by means of phosphorylation at the activation loop, but this 
work defines GRK2 as a kinase upstream of p38 and also as an 
“inactivating MAP2K”, what may have important consequences in the 
regulation of p38 activation subsequent to stimuli that potentiate GRK2 
activity, such as GPCRs. Accordingly, one may envisage a scenario where 
previous GPCR stimulation could lead to an increased pool of pT123-p38 
and thus serve to dampen subsequent p38 stimulation by other stimuli. In 
support of this notion, p38 activity happens to be reduced in end stage 
failing myocardium in humans while the elevation of GRK2 levels is an 
early event in cardiac failure (see ref. (27) for a review). In striking 
accordance, activation of p38 has long been shown to be critical for the 
development of various inflammatory processes including rheumatoid 
arthritis, pulmonary illnesses and inflammatory bowel disease (28). 
Precisely, as mentioned above, a significant reduction of GRK2 levels was 
described in animal models of adjuvant-induced arthritis (21), or human 
rheumatoid arthritis and multiple sclerosis (20, 23), what also points to a 
negative correlation between GRK2 levels and p38 activity, and a 
functional role for GRK2 in the control of p38 activation, that might be 
altered in inflammatory conditions. 
 
GRK2/GIT 
The GIT family of proteins display a complex domain structure, 
including a zinc-finger motif, three ankyrin repeats present in the N-
terminal region of the protein, a Spa2-homology domain (SHD), a coiled-
coiled domain and a paxillin-binding site (PBS). As a result of such 
multidomain architecture, GIT proteins can interact with a variety of 
signalling molecules involved in multiple cellular processes as cytoskeletal 
dynamics, membrane trafficking, cell adhesion and signal scaffolding (29). 
Therefore, the GRK2/GIT1 interaction may be involved in the modulation 
of cell migration processes (5). However, only recently the functional 
consequences and the modulation of such interaction by extra-cellular 
signals have been addressed. Our laboratory has found that GRK2 
positively regulates epithelial cell migration by mechanisms involving 
coordinated fibronectin and S1P-mediated signalling and the modulation of 
the Rac/PAK/MEK/ERK1/2 pathway in response to S1P and adhesion, 
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based on the dynamic regulation of the interaction of GRK2 with GIT1 
(Penela et al., EMBO J., in press). These results suggest that the overall 
contribution of GRK2 to cell migration would be cell-type specific and 
stimulus-specific. This possibility is currently being investigated in our 
group. 
 
In sum, the complex GRK2 "interactome" with multiple signaling 
proteins involved in inflammation and cell migration (summarized in 
Figure 1), its reported alterations in inflammatory disorders and the 
network of mechanisms controlling its activity and expression levels 
suggest key functional roles for GRK2 in inflammation, that deserve to be 
explored in the future. 
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